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Abstract
Neonatal indirect hyperbilirubinemia is one of the most frequent neonatal prob-
lems that affect almost two thirds of term infants. Although etiology of jaundice has 
been widely studied, identification of pathological causes presents constant clinical 
challenge. Our study group performed an extensive retrospective study of etiology 
of neonatal hyperbilirubinemia and showed high frequency (44.37%) of jaundice of 
undefined etiology. The group included exaggerated physiological jaundice, early- 
and late-onset breast-milk jaundice, and no identifiable etiology. Other etiologies 
were neonatal infection, prematurity, birth trauma, and hemolysis represented 
with 15%. We described hematological parameters in both non-hemolytic and 
hemolytic type of jaundice; a significant correlation of relevant laboratory findings 
with etiology was established. In this chapter we will present our own data and 
perform a data-relevant literature review. Furthermore, investigation and manage-
ment plan of neonatal indirect hyperbilirubinemia will be presented in accordance 
with own data and available literature.
Keywords: neonatal indirect hyperbilirubinemia, etiology, undefined jaundice, 
hemolysis, hematological parameters
1. Introduction
Neonatal hyperbilirubinemia is defined as a total serum bilirubin level >5 mg/dL 
(86 μmol/L). This is a frequently encountered problem during the first week of life 
that affects approximately 60% of term and 80% of preterm babies [1, 2]. About 10% 
of breastfed babies are still jaundiced at 1 month of age [1]. The yellowish coloration 
results from deposition of unconjugated bilirubin pigment into the skin and mucous 
membranes [2]. Generally, neonatal jaundice is considered a transitional phenom-
enon without noticeable clinical impact, related to hepatic, red cell, and gastrointes-
tinal immaturity [1, 3]. However, hyperbilirubinemia in the newborn period can be 
associated with severe illnesses such as hemolytic disease, metabolic and endocrine 
disorders, anatomic abnormalities of the liver, and infections [2]. Acute bilirubin-
associated neuropathy caused by a dangerous rise of the total serum bilirubin level 
can often progress into a chronic neurologic condition characterized as kernicterus.  
Update on Critical Issues on Infant and Neonatal Care
2
The latter is characterized by a severe athetoid cerebral palsy, auditory and visual 
problems, dental enamel dysplasia, and, less frequently, intellectual and other 
dysfunctions [1, 2, 4, 5]. Neonatal hyperbilirubinemia develops as an interaction 
between environmental and genetic factors; however, growing attention is turned to 
the genetically determined conditions. Gene variants related with neonatal hyper-
bilirubinemia are those that encode the erythrocyte enzyme glucose-6-phosphate 
dehydrogenase (G6PD), the hepatic isoenzyme uridine diphosphate (UDP) glucuro-
nosyl transferase 1A1 (UGT-1A1), as well as the hepatic solute carrier organic anion 
transporter 1B1 [6–8].
1.1 Pathophysiology of jaundice
Neonatal hyperbilirubinemia results from a predisposition to a higher production 
of bilirubin in newborn infants and their limited ability of bilirubin excretion [9].
Newborns, especially preterm newborns, have higher rates of bilirubin produc-
tion than adults, because they have a higher red cell turnover and a shorter life span. 
Newborns produce bilirubin at a rate of approximately 6–8 mg per kg per day which 
is more than twice the production rate in adults [2].
Other limitations that are evident in newborn infants are decreased hepatic 
uptake of bilirubin from plasma due to decreased ligandin and limited ability to 
conjugate bilirubin due to decreased activity of the hepatic conjugating enzyme 
UDP glucuronosyl transferase (UGT-1A1) [9, 10]. The products of the conjugation 
reaction are transferred via the bile into the intestines. In the newborns’ intestines, 
considerable amount of the conjugated bilirubin is hydrolyzed back to unconju-
gated bilirubin. This reaction is catalyzed by the enzyme beta glucuronidase. The 
unconjugated bilirubin is reabsorbed back into the bloodstream by means of the 
enterohepatic circulation, thus adding an additional bilirubin load to the already-
overstretched liver. Hence, enterohepatic circulation of bilirubin represents an 
important contributor to neonatal jaundice [10].
All the abovementioned features in the newborn infants’ bilirubin metabolism 
contribute concurrently to the appearance of physiologic neonatal jaundice.
Physiologic jaundice refers to the transient increase of the serum bilirubin in 
term infants during the first week of life, followed by a constant decrease over the 
next few weeks to normal levels found in adults. Average peak serum bilirubin 
levels (TSB) found in physiologic jaundice vary between 5 and 6 mg/dL (86 and 
103 μmol/L). Exaggerated form of physiologic jaundice is considered when levels 
of TSB extend to values of 7–17 mg/dL (104–291 μmol/L) [9]. And, when serum 
bilirubin levels increase above 17 mg/dL (291 μmol/L) in term infants, a pathologic 
cause of jaundice should be pursued [2, 9].
1.2 Etiology of pathologic jaundice
According to the mechanism of accumulation of bilirubin, causes of neonatal 
indirect hyperbilirubinemia are classified into three categories (Table 1).
1. Bilirubin overproduction ensues with hemolytic causes of disease such as Coombs-
positive blood group incompatibilities in the ABO, rhesus, or minor blood group 
systems. On the other side of the hemolytic spectrum are the Coombs-negative 
disease causes such as erythrocyte membrane or enzyme defects, defects of 
hemoglobin (Hb) synthesis, sepsis, and some drugs. Bilirubin overproduction 
is also a mechanism of bilirubin accumulation in non-hemolytic disease causes 
such as cephalohematoma, bruising, central nervous system (CNS) hemorrhage, 
polycythemia, and exaggerated enterohepatic circulation [2, 9, 10].
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2. Decreased bilirubin conjugation is present in etiologies such as in physiologic 
jaundice, breast-milk jaundice, Crigler-Najjar syndrome types 1 and 2, 
hypothyroidism, Gilbert syndrome, and glucose-6-phosphate dehydrogenase 
deficiency (G6PD deficiency). Hemolysis was traditionally considered the 
pathophysiological mechanism of jaundice in G6PD deficiency, and indeed 
some known hemolysis triggers such as menthol or Chinese remedies applied 
to the umbilicus for antisepsis have been described in association with this 
etiology of jaundice. Moreover, other assumed triggers of hemolysis, such 
as fava transmitted through human breast milk, chemical cleansers, bacte-
rial and viral infections, and henna applied to the newborn’s skin in some 
cultures of the Middle East, have been described into association with G6PD 
deficiency-linked neonatal hyperbilirubinemia. However, the hematological 
markers of hemolysis such as hemoglobin and hematocrit (Hct) values and 
reticulocyte count have only occasionally been reduced in infants with G6PD 
Increased bilirubin load Decreased bilirubin 
conjugation
Impaired bilirubin excretion
Hemolytic causes
• Positive Coombs test
ABO incompatibility, rhesus 
incompatibility, other blood group 
incompatibilities
• Negative Coombs test
Red blood cell membrane 
defects (spherocytosis, 
elliptocytosis, pyropoikilocytosis, 
stomatocytosis)
Red blood cell enzyme defects 
(G6PD deficiency, pyruvate kinase 
deficiency, other deficiencies)
Hemoglobinopathies (alpha 
thalassemia, beta thalassemia)
Unstable hemoglobins: congenital 
Heinz body hemolytic anemia
Drugs (vitamin K)
Sepsis
Physiologic jaundice
Crigler-Najjar 
syndrome types 1 
and 2
Gilbert syndrome
Hypothyroidism
Breast-milk jaundice
G6PD deficiency
• Biliary obstruction
Biliary atresia, choledochal cyst, 
primary sclerosing cholangitis, 
gallstones, neoplasm, Dubin-Johnson 
syndrome, Rotor’s syndrome
• Infection
Sepsis, urinary tract infection, syphilis, 
toxoplasmosis, tuberculosis, hepatitis, 
rubella, herpes
• Metabolic disorder
Alpha-1-antitrypsin deficiency, cystic 
fibrosis, galactosemia, tyrosinemia, 
glycogen storage disease, Gaucher’s 
disease, hypothyroidism, Wilson’s 
disease, Niemann-Pick disease
• Chromosomal abnormality
Turner’s syndrome, trisomy 18 and 21 
syndromes
• Drugs
Aspirin, acetaminophen, sulfonamides, 
alcohol, rifampin, erythromycin, 
corticosteroids, tetracycline
Non-hemolytic causes
• Extravascular sources
Cephalohematoma, bruising, CNS 
hemorrhage, swallowed blood
• Polycythemia
Fetal-maternal transfusion, 
delayed cord clamping, twin-twin 
transfusion
• Exaggerated enterohepatic 
circulation
Cystic fibrosis, intestinal atresia, 
pyloric stenosis, Hirschsprung’s 
disease, breast-milk jaundice
Information from Refs. [2, 10].
Table 1. 
Classification of neonatal jaundice based on the mechanism of accumulation.
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deficiency-associated hyperbilirubinemia [11, 12]. It has been shown that 
inadequate conjugation capacity of the liver mainly contributes to develop-
ment of neonatal jaundice in G6PD-deficient infants [12–14]. This has been 
proven by significantly lower total serum bilirubin level as well as mono- and 
di-conjugated bilirubin fractions in G6PD-deficient newborns that devel-
oped hyperbilirubinemia than the non-hyperbilirubinemic G6PD-deficient 
newborns [13]. Research that further supports the report that the decreased 
bilirubin conjugation is the main element of jaundice in G6PD-deficient 
newborns has shown varying shortening of red cell life span, which could only 
partially contribute to the jaundice [11, 13]. Moreover, the problem of jaundice 
is potentiated in cases of inherited UDP glucuronosyltransferase promoter 
polymorphism associated with Gilbert syndrome [14, 15]. The combination of 
the two gene mutations has been shown to significantly increase the incidence 
of hyperbilirubinemia in a dose-dependent manner [15].
3. And finally, the third mechanism of jaundice marked by impaired bilirubin 
excretion causes direct (conjugated) hyperbilirubinemia [2, 9, 10, 16]. Neonatal 
sepsis can be featured by both indirect and direct hyperbilirubinemia [2, 16].
1.3 Neurotoxicity of bilirubin
1.3.1 Cellular toxic effects of bilirubin
Even though being of great clinical importance, hyperbilirubinemia neurotoxic-
ity effects on the cellular level are not entirely understood. It has been established 
that the mitochondria could be the primary target of the bilirubin neurotoxicity 
as evidenced by uncoupling of oxidative phosphorylation. Additional effects 
expressed in neuronal tissue include inhibition of DNA synthesis, induction of 
DNA strand breakage, inhibition of protein synthesis, and changes in neurotrans-
mitters’ synthesis and function. Experiments in immature rats have shown associa-
tion between hyperbilirubinemia and impaired cerebral glucose metabolism [9].
1.3.2 Neurotoxicity risk factors
Of specific clinical importance is to recognize the risk factors associated with 
brain damage in newborn infants with significant hyperbilirubinemia. According to 
the 2009 AAP recommendation, neurotoxicity risk factors are isoimmune hemo-
lytic disease, G6PD deficiency, asphyxia, sepsis, acidosis, and albumin <3.0 mg/dL 
[17]. The neurotoxicity risk factors are used in making the decision when to initiate 
phototherapy or perform an exchange transfusion. These interventions are recom-
mended at a lower bilirubin threshold level in the presence of any of the neurotoxic-
ity risk factors [17].
Prematurity represents a well-recognized predisposition to development of 
jaundice. In premature newborns the rise of the total serum bilirubin tends to be 
slightly slower but of longer duration than term newborns [18]. There is still insuf-
ficient amount of evidence-based data to provide recommendations for treatment in 
this group of patients. Recommendations are mainly based on consensus agreement-
based guidelines on the safe spectrum of thresholds [19, 20]. Bilirubin neurotoxicity 
has been associated with prematurity; however, birth weight and gestation are 
not the sole variables predictive of the neuronal damage. Other factors such as the 
presence of a concurrent neonatal disease, sepsis, cholestasis, drugs that alter the 
albumin-bilirubin binding, or the use of total parenteral nutrition have been found 
to enhance the risk of neurotoxicity. Moreover, premature newborns have similar 
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but often more subtle clinical manifestations of acute bilirubin encephalopathy than 
term infants [21–23]. For all the abovementioned reasons, it is reasonable to observe 
premature newborns as a distinct entity of neonatal jaundice and not assign them to 
an “undetermined etiology” group as done by certain authors [16].
1.3.3 Kernicterus
This term refers to the neurologic consequences of the deposition of unconju-
gated bilirubin in brain tissue with subsequent damage and scarring of the basal 
ganglia and brainstem nuclei. Determinants of the neurotoxic effect of bilirubin 
are the duration of exposure and the concentration of bilirubin in the brain. Poor 
correlation exists between serum bilirubin level and bilirubin encephalopathy in the 
absence of hemolysis [9]. Other important determinants of bilirubin influx in the 
brain are the bilirubin-binding capacity of albumin and the integrity of the blood-
brain barrier. If the serum unconjugated bilirubin level exceeds the bilirubin-binding 
capacity of albumin, unbound lipid-soluble bilirubin crosses the blood-brain barrier. 
Conditions that alter the permeability of the blood-brain barrier such as sepsis, aci-
dosis, hypoxia, hyperoxia, hypoperfusion, and hyperosmolality can potentiate bili-
rubin entry in the brain [2, 9]. Differentiating neurons are particularly sensitive to 
bilirubin-related injury; therefore, premature newborns are more susceptible to the 
effects of bilirubin deposition in the brain [9]. For the purpose of greater consistency 
when defining bilirubin-induced neurological damage, it has been recommended to 
separate the terms “acute bilirubin encephalopathy” and “kernicterus.” The former 
is used to describe the acute manifestations of bilirubin toxicity in the first weeks of 
life, whereas the latter is reserved for the chronic and permanent clinical sequelae of 
bilirubin toxicity [4]. The exact bilirubin concentration associated with kernicterus 
in the healthy term infant is unpredictable. Toxicity levels may vary among ethnic 
groups, also with maturation of an infant, and in the presence of hemolytic disease. 
The clinician’s concerns of possible bilirubin toxicity should rise in the presence 
of bilirubin >25 mg/dL (428 μmol/L) in the term newborn without hemolysis and 
> 20 mg/dL (342 μmol/L) in the term newborn with hemolysis [2]. The early phase 
of acute bilirubin encephalopathy is characterized by lethargy, hypotonia, and poor 
sucking. In the intermediate phase, irritability and hypertonia develop. The infant 
may develop a fever and high-pitched cry, which may alternate with drowsiness 
and hypotonia [4, 24]. The hypertonia is demonstrated by backward arching of the 
neck (retrocollis) and trunk (opisthotonos). The advanced phase is characterized by 
pronounced hypertonia, apnea, and fever, deep stupor to coma, sometimes seizures, 
and death. Features of chronic bilirubin encephalopathy (kernicterus) include 
athetoid cerebral palsy, hearing loss, visual and dental problems, and moreover 
intellectual and other handicaps [1, 2, 4, 5, 9, 10].
1.4 Laboratory evaluation of jaundice
Laboratory evaluation of jaundice is directed by the age of the newborn. The 
first step in evaluation, for a newborn jaundiced in the first 24 hours of life, is to 
perform total serum bilirubin (TSB) or transcutaneous bilirubin (TcB) measure-
ment [2, 4, 10]. Transcutaneous bilirubin (TcB) can be a powerful and noninvasive 
screening tool for bilirubin estimation with reported close correlation to TSB 
measurement in different populations [10]. When jaundice appears excessive for 
newborn’s age, a TSB should be obtained. In infants under phototherapy and TSB 
above the 75th percentile or rising rapidly (i.e., crossing percentiles), it is recom-
mended to extend the diagnostic workout by performing additional tests such as 
complete blood count and smear, reticulocyte count, blood grouping, and Coombs 
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test as well as end-tidal carbon monoxide levels. In cases of specific ethnic origin 
or positive family history, analysis of G6PD and pyruvate kinase deficiencies is 
considered. Once direct (or conjugated) bilirubin level is elevated, urinalysis, urine 
culture, and evaluation for sepsis are recommended. As per jaundice persisting 
beyond the third week of life, a diagnostic protocol for identification of cholestasis 
causes should be followed [2, 4, 10].
1.5 Treatment of jaundice
1.5.1 Phototherapy
It is a standard method for treatment of hyperbilirubinemia that is applied when 
bilirubin levels exceed gestation and hour-specific treatment thresholds [1, 4, 9, 
25–27]. It is effective through photoisomerization of bilirubin to a water-soluble 
product that is readily excreted via bile or urine. The efficacy depends on the 
wavelength and the dose of the delivered light, as well as on the illuminated skin 
surface area [9, 27]. Specific phototherapy treatment graphs have been developed to 
address the phototherapy needs in term and in preterm babies [10, 26, 27]. General 
measures are involved concurrently to phototherapy such as maintenance of fluids 
and treatment of underlying disease cause such as infection [27].
1.5.2 Exchange transfusion (ECT)
It is a method for rapid elimination of the bilirubin and the circulating antibodies 
from the circulation, therefore most beneficial in cases of ongoing hemolysis. Small 
amount of blood are removed through a central venous catheter and replaced with the 
same amount of donor red blood cells suspended in plasma. The procedure is repeated 
until twice the blood volume of the newborn is replaced with the donor blood. This 
procedure involves multiple complications among which most pronounced are graft-
versus-host disease, necrotizing enterocolitis, and portal thrombosis [1, 9]. Although 
being the first therapy for severe jaundice, this intervention is becoming virtually 
obsolete and reserved only for cases of severe hyperbilirubinemia that could not be 
managed by intensive phototherapy. Likewise phototherapy, exchange transfusion 
treatment threshold graphs have been devised for term and preterm gestations to serve 
as clinical guidance for initiation of therapy [10, 26, 27]. Exchange transfusion should 
only be performed in highly developed neonatal intensive care units (NICU) adequately 
equipped for monitoring and resuscitation as well as with trained personnel [4].
1.5.3 Pharmacologic therapies
These drugs interfere with variable effectiveness at different stages of the 
bilirubin metabolism. For example, phenobarbital has been used to improve the 
conjugation and excretion of bilirubin. Tin mesoporphyrin inhibits heme oxygenase 
thereby acting on the production of bilirubin. Other drugs are involved with the 
enterohepatic circulation of bilirubin [9, 10]. Intravenous immunoglobulin has 
been shown to significantly reduce the need for exchange transfusion in Rh or ABO 
hemolytic disease [4].
2. Neonatal hyperbilirubinemia in the Republic of North Macedonia
Our study group performed an extensive retrospective study for the purpose of 
evaluation of the etiology and management of indirect hyperbilirubinemia at the 
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University Pediatric Clinic in Skopje (UPCS), now Republic of North Macedonia 
(RNM). The study group included 284 newborns who had been admitted to the 
neonatology department at the University Pediatric Clinic in Skopje with the 
diagnosis of neonatal indirect hyperbilirubinemia during the period of 2 years [28]. 
They represented one quarter of the total number of 1126 hospitalized patients 
during this period in a tertiary level university teaching clinical hospital setting. 
Relevant history, clinical data, laboratories, and the type of therapy applied were 
retrieved from the medical records, recorded on questionnaires, and statistically 
analyzed. Perinatal history data of relevance were birth parameters, Apgar scores, 
and delivery mode. Clinical presentations that could potentially influence duration 
and intensity of jaundice had been searched for such as hematomas, cephalohe-
matoma, intracranial hemorrhages, hypothyroidism, impaired intestinal motility, 
and infection. All laboratories and investigations of relevance were recorded, as 
well as the therapies applied. Moreover, the day of the bilirubin peak was noted, as 
well as two subsequent bilirubin measurements. Standard techniques for analysis 
of blood count and smear, bilirubin and fractions, serum aminotransferases, and 
G6PD, as well as infants’ and mothers’ blood group and direct antiglobulin Coombs 
test (DAT), were applied as described elsewhere [12, 28]. Statistical Package for the 
Social Sciences (SPSS) for Windows (SPSS Inc., Chicago, IL, USA) was used for 
the statistical analyses. Absolute numbers and percentages were used to present the 
categorical variables, whereas mean, standard deviation, minimum, maximum, 
median, and rang were used to present the quantitative variables. Testing of sig-
nificance between groups was performed using Kruskal-Wallis test, student t-test, 
Mann–Whitney U test, and analysis of variance. The result was considered signifi-
cant if probability value (p) was <0.05 and <0.01 for high significance. Nine types 
of jaundice had been identified and grouped as follows: (1) ABO incompatibility, 
(2) rhesus (Rh) incompatibility, (3) cephalohematoma and bruising, (4) sepsis, 
(5) prematurity, (6) intracranial hemorrhage, (7) hemolysis (neither ABO nor Rh 
incompatibility), (8) Down syndrome, and (9) undefined. The highest prevalence 
was found for jaundice of undefined etiology (44.37%), and the second most 
prevalent was etiology of neonatal infection represented with 19.37%. Hemolytic 
etiologies were represented with 8.45% for ABO incompatibility, 5.63% for Rh 
incompatibility, and 0.35% for hemolysis neither ABO nor Rh or in total 14.43%. 
Least prevalent were cephalohematoma and bruising due to birth trauma (2.82%), 
intracranial hemorrhage (2.46%), and Down syndrome (0.70%) (Table 2) [28].
Etiology of sepsis was assigned to newborns with a positive blood/cerebrospinal 
fluid culture or clinically relevant infection requiring antibiotic therapy. Subjects that 
had sepsis and elevated direct bilirubin were not included [2, 28]. Prematurity, defined 
as less than completed 37 weeks of gestational age, was considered a distinct etiology 
of jaundice. Our group of undefined etiology included cases of early- and late-onset 
breast-milk jaundice, exaggerated physiological jaundice, [2, 9, 28], and no identifiable 
etiology. Cephalohematoma and bruising were representatives of birth trauma.
2.1 Undefined etiology of jaundice
We found a high percentage of jaundice of undefined etiology (44.37%). 
Another study reported higher prevalence of undetermined etiology (75.8%) [16]. 
Clinical evaluation of severe neonatal hyperbilirubinemia in a resource-limited 
setting similarly showed highest prevalence of idiopathic jaundice (33.3%) [24]. No 
cause for the extreme hyperbilirubinemia of ≥25 mg per dL (428 μmol per L) could 
be identified in 65.6% of cases admitted for treatment at the NICU in Southern 
Turkey [29]. Etiology was unknown in 11 of the 79 ECT cases (13.9%) in the Eastern 
Mediterranean region of Turkey as reported by Davutoğlu et al. [30]. Dissimilarly, 
Update on Critical Issues on Infant and Neonatal Care
8
we did not find undefined etiology among our ECT cases. It could be assumed that 
the variable prevalence of “undefined etiology” reported in different studies was a 
result of diverse classification of the causes of neonatal jaundice and also of dif-
ferent levels of TSB considered (pathologic or extreme). We described undefined 
etiology as such, where intensive workout could not provide an identifiable cause or 
contributing factor for jaundice. Through a careful selection process, a homogenous 
group of clinically stable patients was obtained that had normal birth parameters 
and required treatment with phototherapy (Table 3). We speculated that an 
imbalance between bilirubin production and conjugation was the primary concept 
of jaundice in this group since no history, clinical, and laboratory data existed to 
indicate another mechanism of jaundice [28, 31].
Mean Min Max M Interquartile range
Age 4 ± 2.5 2 14 3 3–4
GW 39 ± 1.2 37 42 39 38–40
BW 3247.1 ± 437.4 2200 4500 3245 2980–3500
BL 50.2 ± 1.8 46 56 50 49–51
Mode of delivery N %
Spontaneous 114 90.47
CS 9 7.14
Vacuum extraction 2 1.59
Forceps 1 0.8
Perinatal hypoxia N %
No 109 86.51
AS 7 16 12.7
AS 4–6 1 0.79
Min, minimum; Max, maximum; M, median; GW, gestation weeks; BW, birth weight; BL, birth length; CS, cesarean 
section; AS, Apgar score. Information from Ref. [28].
Table 3. 
Basic characteristics of the undefined etiology group at UPCS, RNM.
Etiology Number Percentage (%)
Undefined etiology 126 44.37
Neonatal infection 55 19.37
Prematurity 45 15.85
ABO incompatibility 24 8.45
Rh incompatibility 16 5.63
Cephalohematoma and bruising due to birth trauma 8 2.82
Intracranial hemorrhage 7 2.46
Hemolysis (neither ABO nor Rh incompatibility) 1 0.35
Down syndrome 2 0.70
Total 284 100
Information from Ref. [28].
Table 2. 
Causes of neonatal indirect hyperbilirubinemia in the republic of North Macedonia.
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The basic characteristics of the undefined etiology group are presented in 
Table 3. Newborn infants of this group were generally delivered spontaneously 
(90.47%) with normal birth parameters [birth weight (BW) and birth length (BL)] 
and did not suffer major perinatal hypoxia. The median (interquartile range) age of 
presentation of jaundice was at day 3 (3–4) (Table 3). In the group of undefined eti-
ology, the median (interquartile range) day at which bilirubin reached its peak was 
9 (6–17). The median (interquartile range) of the peak TSB level was 324 (270–394) 
μmol/L, whereas the mean ± standard deviation (SD) peak serum bilirubin concen-
tration was 333.4 ± 91.1 μmol/L.
Statistical analyses included comparison of laboratory parameters between five 
etiological groups: (1) hemolytic etiology of jaundice including ABO incompat-
ibility, Rh incompatibility, and hemolysis (neither ABO nor Rh incompatibility), 
(2) neonatal infection/sepsis, (3) prematurity, (4) hematomas (cephalohematoma, 
bruising, intracranial hemorrhage), and (5) undefined etiology.
To summarize the analyzed laboratory parameters, mean peak bilirubin levels 
in newborns with hemolysis (group 1) were shown to be statistically significantly 
higher than levels in the groups with neonatal infection, prematurity, and hema-
tomas (groups 2, 3, and 4). The first control serum bilirubin level was significantly 
higher in newborns with hemolysis (group 1) than prematurity and undefined 
etiology (groups 3 and 5). No statistically significant differences were found in 
the second control bilirubin measurement; also levels of hepatic transaminases 
(AST and ALT) were not found to depend significantly on the etiology of jaundice. 
Estimation of hepatic transaminases has not proven of substantial influence on 
jaundice workout and management.
2.2 Prematurity and jaundice
Premature newborns, due to physiological characteristics, associated risk 
factors, and proneness to development of pronounced jaundice, were assigned a 
separate etiological group contrary to assignment of these patients into the “unde-
termined etiology” performed by other authors [16]. We were able to show slower 
increase toward the peak bilirubin level in the group of premature newborns than 
in groups of hemolysis, hematomas, and infection. Levels of erythrocytes (Er), 
hemoglobin (Hb), and hematocrit (Hct) in premature newborns were statistically 
significantly lower than the groups of undefined etiology and infection.
2.3 G6PD deficiency
We did not find cases of G6PD deficiency in the studied group. Although no 
cases of G6PD deficiency were confirmed, a standard was set for a new quan-
titative spectrophotometric assay for G6PD detection, thereby overcoming the 
uncertainties connected with the previously used qualitative methods. Previous 
qualitative studies of the G6PD deficiency in Macedonia are those of Fraser et al. 
[32] and of Andreeva et al. [33]. The first group of authors assessed the average 
prevalence of the G6PD deficit in Yugoslavia from 1% [32] based on tests car-
ried out on 144 samples from then Republic of South Macedonia and 512 samples 
from the region of Dalmatia. The second group of authors in 1974 examined the 
prevalence of the G6PD deficiency in 3263 male school children from the area of 
Southeastern Macedonia (territory of nowadays Republic of North Macedonia) 
and showed a frequency of 1–2% of the G6PD deficit in that part of the republic. In 
the second examination of the same group of authors, realized on samples of 1196 
male school children from the territory of Skopje, when processing the enzyme, 
it was concluded that it was a Mediterranean variant and the prevalence of the 
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deficit of 1.02% was reported among the children of Macedonian nationality and 
6.63% for Roma children [33]. Quantitative testing for G6PD deficiency has been 
recommended to be performed, thus avoiding partially G6PD-deficient patients 
such as heterozygous females to be missed [34, 35]. As much as 1/3 higher levels of 
G6PD in the neonatal period can be encountered due to the presence of physiologic 
polycythemia in this period [35]. Therefore, it is reasonable to schedule for another 
subsequent test in cases of borderline normal results and a specific ethnic origin.
In a subsequent neonatal jaundice study, we showed an incidence of 8.57% of 
G6PD-deficient infants in a strictly prospectively selected group of infants with 
jaundice of undetermined etiology (own unpublished results). From this study, a 
population-specific range of normal values for the G6PD quantitative spectropho-
tometric assay will be derived.
2.4 Extravasation of blood and jaundice
A separate group of patients with hematomas was developed, encompassing 
patient with extravascular collections of blood where an increased bilirubin load 
was presumed the fundamental mechanism of hyperbilirubinemia [2, 9, 16, 18, 28]. 
No statistically significant hematological correlations between this group and the 
other four groups of patients were found.
2.5 Infection-associated jaundice
Sepsis is a known perinatal risk factor for both unconjugated and conjugated 
jaundice [2, 9, 18] and is also listed as a risk factor for hyperbilirubinemia neuro-
toxicity [17]. Analysis of prevalence rates in different regions of the world showed 
varying importance of infection in connection with jaundice. Highest variability of 
prevalence rates was reported in Asia (from 9.7 to 31.2%). In Africa infection was 
related with over 13.9% of the hyperbilirubinemia or kernicterus cases, whereas 
in Europe and North America, infection was related with 14.3% of the kernicterus 
cases [1].
In our study, the group of infection-associated jaundice was represented 
with 19.37%. On the contrary, sepsis was found in almost twice as much (35.3%) 
severe hyperbilirubinemia cases in South East Nigeria [24]. Similar to the North 
Macedonian study, sepsis was present in 15.7% indirect hyperbilirubinemia cases at 
Zanjan Province of Iran [16]. We assumed our figure an overrepresentation due to 
the fact that not only culture positive cases were included but also newborns with 
clinical or biochemical markers of sepsis. Reliable discrimination between culture 
positive and culture negative cases was not possible due to the variety of process-
ing of initial hemoculture between the tertiary level and the referral hospitals. 
Therefore, the term “infection” rather than “sepsis” was used for more accurate 
reflection on this group of patients. Statistically significant higher levels of hemato-
logical parameters (Er, Hb, and Hct) were shown for this group than the hemolytic 
group and the premature newborns.
2.6 Hemolytic jaundice
We have established a group of hemolytic jaundice according to the mechanism 
of the hyperbilirubinemia employed in cases of ABO and Rh isoimmunization. 
According to the 2009 update on the management of newborn infants ≥35 weeks’ 
gestation, isoimmune and other hemolytic diseases (e.g., G6PD deficiency) were 
included in two important of risk factors’ categories: severe hyperbilirubinemia 
and hyperbilirubinemia-induced neurotoxicity [17]. Furthermore, it has been 
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postulated that DAT-positive isoimmune hemolytic disease and severe hyperbiliru-
binemia exert synergistic effect in potentiating the bilirubin-induced neurotoxicity 
[36]. Lower phototherapy and exchange transfusion threshold levels have been rec-
ommended in isoimmune hemolytic disease in order to prevent the acute manifesta-
tions of bilirubin toxicity that might evolve into chronic neurological condition, 
kernicterus, also a pre-discharge risk assessment and early post-discharge follow-up 
[4, 17, 25–27]. Tiker et al. report isoimmunization in 19 out of 93 (20.43%) patients 
admitted for treatment of extreme hyperbilirubinemia in Southern Turkey [29]. 
ABO isoimmunization was reported the most common cause of hyperbilirubinemia 
requiring ECT in two other studies performed in Turkey; the reported rates were 
38% and 27.8%, respectively [30, 37]. ABO incompatibility was present in 8.45% of 
our study cases. Rh incompatibility was represented with 5.63% of all hyperbilirubi-
nemia cases. We found one hemolysis positive patient who had neither ABO nor Rh 
incompatibility. The pooled prevalence of all hemolytic etiology cases in our study 
was 14.43%. When compared to the groups of neonatal infection, prematurity, and 
hematomas, the group of hemolytic etiology presented with significantly higher 
peak bilirubin levels. A statistically significant higher level of bilirubin in hemo-
lytic etiology than prematurity and undefined etiology was also noted on the first 
control bilirubin level estimation. This observation pointed out a slower tendency 
of reduction of bilirubin under phototherapy in hemolysis than undefined etiology. 
However, the majority of cases with hemolytic etiology (97.89%) were managed 
conventionally by phototherapy using double-surface blue light phototherapy lamps 
at wavelength of 460 nm, and only 2.11% Coombs-positive ABO/Rh incompatibility 
patients were treated by exchange transfusion.
2.7 Laboratory analyses
A comparison of hematological and biochemical parameters was performed 
between groups of patients with undefined (unspecified) etiology (126 patients, 
74.5%) and 41 patients with ABO or rhesus-type hemolytic disease of the new-
born (24.6%).
The group of newborns with ABO/Rh incompatibility presented with sig-
nificantly lower mean values of all analyzed hematological parameters than the 
group of jaundice with unspecific etiology [hemoglobin (p = 0.038), erythrocytes 
(p = 0.0023), and hematocrit (p = 0.037)] (Table 4) [38]. Mean reticulocyte count 
was significantly higher (p = 0.000036) in the group of ABO/Rh incompatibility 
(27.88 ± 26.4 vs. 11.94 ± 7.4). The group of hemolytic etiology was characterized by 
significantly earlier jaundice appearance (p < 0.01) than the group of jaundice of 
unspecified etiology. The mean ± standard deviation (SD) for hemolysis group was 
2.63 ± 2.4 days versus 4.02 ± 2.5 days for the unspecified etiology group. The peak 
bilirubin level (mean ± SD) in hemolysis group of 379.76 ± 133.5 μmol/L was higher 
than unspecified etiology (333.44 ± 91.1 μmol/L) although the differences were 
not statistically significant (p = 0.052). Statistically insignificantly higher levels at 
the first (p = 0.062) and second (p = 0.448) control bilirubin measurements were 
registered for the hemolytic etiology group than the unspecific jaundice group.
On the other hand, duration of the bilirubin peak was significantly lengthier 
(p = 0.036) for the group of unspecific jaundice. The mean ± SD for this group was 
15.03 ± 25.7 days versus 10.22 ± 9.02 days for the ABO/Rh incompatibility group 
(Table 5) [38].
Despite the fact that we did not show statistically significant higher peak levels 
of bilirubin in the hemolytic etiology group than the other group of jaundice, a 
propensity toward faster elevation of bilirubin and more pronounced level of 
jaundice was noted. The peak bilirubin level showed significantly longer duration 
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Groups Descriptive statistics
N Mean ± SD Median Min-max t-value, p
Ret
ABO/Rh 41 27.88 ± 26.4 22.0 2–121 Z = 4.13
p = 0.000036**
Unspecified 126 11.94 ± 7.4 11.0 1–39
Day of bilirubin peak
ABO/Rh 41 2.63 ± 2.4 2.0 1–14 Z = 5.78
p = 0.000**
Unspecified 126 4.02 ± 2.5 3.0 2–14
Peak bilirubin level (μmol/L)
ABO/Rh 41 379.76 ± 133.5 364.0 158–801 Z = 1.95
p = 0.052 NS
Unspecified 126 333.44 ± 91.1 324.0 107–598
Duration of the bilirubin peak (days)
ABO/Rh 41 10.22 ± 9.02 6.0 1–37 Z = 2.09
p = 0.036*
Unspecified 126 15.03 ± 25.7 9.0 2–279
First control bilirubin (μmol/L)
ABO/Rh 40 274.2 ± 124.9 235.5 96–682 Z = 1.87
p = 0.062 NS
Unspecified 112 227.39 ± 80.7 211.5 60–473
Second control bilirubin (μmol/L)
ABO/Rh 24 227.46 ± 83.4 206.0 111–437 Z = 0.76
p = 0.448 NS
Unspecified 48 221.92 ± 48.3 228.5 51–314
*p < 0.05.
**p < 0.01.
Z, (Mann-Whitney U test); N, number of patients; SD, standard deviation; p, probability value; NS, not significant. 
Information from Ref. [38].
Table 5. 
Reticulocytes and bilirubin analyses in neonatal jaundice, comparison between ABO/Rh incompatibility and 
unspecified etiology groups.
Groups Descriptive statistics
N Mean ± SD Min-max t-value, p
Hb (g/L)
ABO/Rh 41 155.02 ± 30.3 74–218 t = 2.09 p = 0.038*
Unspecified 126 165.36 ± 26.5 105–224
Er (×1012)
ABO/Rh 41 4.29 ± 0.8 2.05–5.81 t = 3.09 p = 0.0023*
Unspecified 126 4.67 ± 0.6 3.27–6.58
Hct (%)
ABO/Rh 41 41.35 ± 8.9 18.9–61.9 t = 2.11 p = 0.037*
Unspecified 126 44.26 ± 7.2 28.4–64.6
*p < 0.05.
t, student t-test; N, number of patients; SD, standard deviation; p, probability value. Information from Ref. [38].
Table 4. 
Hematological parameters in neonatal jaundice, comparison between ABO/Rh incompatibility and unspecified 
etiology groups.
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in the group of unspecific jaundice. It remains speculative whether this was due to 
different mechanisms of jaundice involved, different responses to the phototherapy 
applied, or other influences such as diverse stringency to phototherapy.
According to an evidence-based review on neonatal hyperbilirubinemia, the 
majority of kernicterus cases occurred in infants with a bilirubin level higher 
than 20 mg/dL (342 μmol/L) [39]. It was obvious that our hemolysis cases with 
mean peak bilirubin levels of 379.8 ± 133.5 μmol/L were eligible for the neurotoxic 
effects of the hyperbilirubinemia, especially the ones toward the higher end of the 
spectrum and candidates for long-term neurodevelopmental follow-up. Therefore, 
clinicians’ awareness of potential treats and harms that might be associated with 
isoimmunization is vital.
3. Conclusions
Neonatal indirect hyperbilirubinemia is a common phenomenon during the first 
week of postnatal life affecting almost two thirds of term newborns. The mecha-
nism of neonatal jaundice is multifactorial, involving delicate balance between 
processes that potentiate bilirubin production and the ones that diminish bilirubin 
clearance. Although etiology of jaundice has been widely studied, identification of 
pathological causes presents constant clinical challenge.
Hyperbilirubinemia was found to be a common clinical presentation at the 
neonatology department of the University Pediatric Clinic in Skopje, Republic of 
North Macedonia, and encompassing one quarter of the hospitalized patients. Most 
cases suffered from a less severe jaundice of undefined etiology that had tendency 
to longer duration. Almost 15% of the hyperbilirubinemia cases presented with 
hemolytic causes of jaundice that had earlier and more severe peak of the bilirubin 
level. Those required immediate clinicians’ attention and prompt management plan 
and were candidates for subsequent neurodevelopmental follow-up.
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